Anjarium Biosciences Raises $61M in Series A Financing

16 Sep, 2021

Anjarium Biosciences Raises $61M in Series A Financing
Photo by David Milmont on Unsplash

– Anjarium Biosciences AG is a Schliren, Zurich-based biotech company focused on creating and delivering a new class of non-viral gene therapies.
– Series A funding closed at $61m.
– The round was co-led by Abingworth and Gimv, with participation from Omega Funds, Pfizer Ventures and Surveyor Capital (a Citadel company).
– The new investment will be used to advance the company’s pipeline programs towards clinical development.

Biotechnology Pharmaceutical Western Europe
Crunchbase icon

Content report

The following text will be sent to our editors: